Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Antibody-Drug Conjugates Market Report Overview

An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others.

There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors.

The ADC market research report will aid clients in gaining insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology. The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. The report also offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space. Additionally, the report provides commentary on the latest trends in ADC development including payload and linker analysis.

Key Marketed Drugs ·       Daiichi Sankyo’s Enhertu

·       Gilead’s Trodelvy

·       Genmab’s Tivdak

·       Rakuten Medical’s Akalux

Key Pipeline Drugs ·       Ambrx Biopharma’s ARX788

·       Bispecific ADC Alphamab Oncology’s JSKN003

·       Daiichi Sankyo & AstraZeneca’s DS-1062

·       Daiichi Sankyo’s U-31402

Key Players ·       Daiichi Sankyo

·       Pfizer

·       Roche

·       AstraZeneca

·       Hengrui Medicine

·       AbbVie

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Antibody-Drug Conjugates (ADC) – Marketed Drugs

The key marketed drugs in the ADC market are Daiichi Sankyo’s Enhertu, Gilead’s Trodelvy, Genmab’s Tivdak, and Rakuten Medical’s Akalux among others.

Daiichi Sankyo’s Enhertu: This drug is considered best-in-class ADC approved in multiple indications where HER2 is prevalent. Its key strength includes a high drug-antibody ratio with eight deruxtecan payload molecules conjugated to each trastuzumab mAb, for a higher antitumor effect. It also has higher efficacy in terms of OS and PFS versus Kadcyla in mHER2 BC.

Antibody-Drug Conjugates (ADC) Market Analysis by Marketed Drugs

Antibody-Drug Conjugates (ADC) Market Analysis by Marketed Drugs

Buy the Full Report for More Insights on the Key Marketed Drugs in the ADC Market

Download a Free Sample Report

Antibody-Drug Conjugates (ADC) – Pipeline Drugs

The key pipeline drugs in the ADC market are Ambrx Biopharma’s ARX788, Bispecific ADC Alphamab Oncology’s JSKN003, Daiichi Sankyo & AstraZeneca’s DS-1062, and Daiichi Sankyo’s U-31402 among others.

Daiichi Sankyo’s Enhertu: This is a first-in-class HER3-directed deruxtecan ADC product. The ADC received breakthrough designation and priority review of its BLA from the FDA for 3L+ EGFR mutated NSCLC.

Antibody-Drug Conjugates (ADC) Market Analysis by Pipeline Drugs

Antibody-Drug Conjugates (ADC) Market Analysis by Pipeline Drugs

Buy the Full Report for More Insights on the Key Pipeline Drugs in the ADC Market

Download a Free Sample Report

Antibody-Drug Conjugates (ADC) – Competitive Landscape

The key players in the ADC market are Daiichi Sankyo, Pfizer, Roche, AstraZeneca, Hengrui Medicine, and AbbVie among others.

Daiichi Sankyo Co Ltd: Daiichi Sankyo is headquartered in Tokyo, Japan. It is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia.

Antibody-Drug Conjugates (ADC) Market Analysis by Players

Antibody-Drug Conjugates (ADC) Market Analysis by Players

Buy the Full Report for More Insights on the Key ADC Players

Download a Free Sample Report

Scope

  • Clients will gain insight into the competitive landscape of leading antibody-drug conjugates (ADC) through this report.
  • The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players.
  • The report offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space.
  • The report provides commentary on the latest trends in ADC development including payload and linker analysis.

Reasons to Buy

Our modality-specific reports answer questions such as –

  • What is the future global market value of ADCs in Oncology?
  • Which cancer types are more likely to receive these therapies?
  • What are the clinical benchmarks for currently approved ADCs?
  • What are the emergent linkers and payloads for ADCs?
  • What is the key opinion leaders’ outlook for the products?
  • What are key opportunities and challenges in the area?

Frequently asked questions

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges standard reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges in real time.

  • Access a live Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.